Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous mesenchymal stem cells (MSCs) developed by the Chinese University of Hong Kong are an investigational cell therapy for the treatment of knee osteoarthritis. The procedure involves harvesting MSCs from the patient's own bone marrow, which are then processed and injected intra-articularly into the affected knee joint. These cells are hypothesized to alleviate osteoarthritis symptoms and promote joint health through several mechanisms: they can differentiate into chondrocytes to potentially repair cartilage defects, and they release a variety of paracrine factors (including cytokines and growth factors) that exert anti-inflammatory and immunomodulatory effects. This dual action aims to reduce joint pain, improve function, and slow the progression of cartilage degeneration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Autologous mesenchymal stem cells (Chinese University of Hong Kong).